About this trial
Sugammadex is a medication used for reversal of muscle relaxation during procedures under general anesthesia. It works by encapsulating muscle relaxant molecules with a steroid ring in its structure. On the other hand, postoporative nause and vomiting (PONV) is an adverse outcome during anesthesia. PONV can be prevented with pharmacologic agents such as ondansetron and dexamethasone. Dexamethasone is a steroidal agent that can interact with sugammadex. In theory, this interaction could lead to reduced effectiveness of sugammadex. In fact, several studies have explored this interaction. However, the effect of sugammadex on the antiemetic effect of dexamethasone has not been evaluated. This study intends to evaluate this interaction.
Eligibility criteria
Qualifiers
Older than 18 years old
Elective surgery
ASA 1, 2, 3
At least one risk factor for PONV
Disqualifiers
Pregnancy
Receiving antiemetics prior to arrival to preoperative holding area
Receiving opioids prior to arrival to preoperative holding area
Admission to ICU
Trial design
Treatments tested in this trial
- Not listed